CrossingBridge Ultra-Short Duration ETF SPC
Set alert
18.98 USD +0.48 +2.59%
At close · Jan 27
18.70 -0.28 -1.48%
After hours · Jan 27, 4:00 PM ET
18.58 Day range 19.00
21.10 52-week range 21.87
- YTD
- -0.11%
- 1 year
- -10.93%
- Open
- 18.99
- Prev close
- 18.50
- Mkt cap
- 18.39M
- Vol
- 3.61K
- Avg vol
- 14.91K
- EPS
- 0.00
- P/E
- 32.33
- Div yield
- 0.00%
More statistics
- Low
- 18.58
- High
- 19.00
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 21.67
- 200-d avg
- 21.63
3M chart
Events in this range
- Dec 24, 2025Dividend: 2.67038
Signals (8)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Jan 21, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 15, 2026 | 9 months ago |
| RSI: Oversold | Dec 24, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 12, 2025 | 11 months ago |
| RSI: Overbought | Nov 5, 2025 | 12 months ago |
| RSI: Overbought | Nov 3, 2025 | 12 months ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 32.33
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 21.67
- 200-day average
- 21.63
About CrossingBridge Ultra-Short Duration ETF
The fund is an actively managed exchange-traded fund (“ETF”) that under normal market conditions will invest at least 80% of its net assets, plus borrowings for investment purposes, in shares of common stock and units of Special Purpose Acquisition Companies (“SPACs”) that have yet to consummate a shareholder-approved merger or business combination. The fund seeks to invest in publicly-traded SPACs that at the time of purchase are trading at or below the SPAC’s pro rata trust account value. The fund is non-diversified.
News
- Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
- Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
- Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
- Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
- Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
- SPC Financial Inc. Sells 970 Shares of NVIDIA Corporation $NVDA
- Chipotle to Debut in Asia With SPC Group to Expand Global Footprint
- Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
- Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
- CrossingBridge Pre-Merger SPAC ETF (Nasdaq: SPC) Designates Cash Creation/Redemption the Default Order Type in Effort to Reduce Trading Volatility and Enhance Liquidity
Your note
Sign in to keep a note on SPC — it syncs with the Stock Master app.